VP, Clinical Operations
has twenty years of experience managing global Phase I to Phase IV clinical studies focusing on various indications. Prior to joining Retrotope, Mr. Heerinckx served as Associate Director of Clinical Operations at Theravance for three years, where he lead the anti-infectious disease program overseeing a global Phase 3 study in treatment of bacteremia with an IV antibiotic drug. Prior, Mr. Heerinckx lead a clinical operations team at Anacor Pharmaceuticals overseeing studies in support of the development of three molecules.
M. Heerinckx worked extensively on Phase 3 studies in the treatment of onychomycosis with a topical drug, and Phase 2 studies in the treatment of psoriasis and atopic dermatitis with a topical drug. Prior, Mr. Heerinckx worked at ARYx Therapeutics as Sr. Clinical Program Manager for three years where he managed a large global Phase 2 clinical study of anti-arrhythmic drug with 70 sites in four countries.
Mr. Heerinckx also held various positions in clinical research at Scios, Inc. for nearly 10 years, where he managed and planned several studies from 1996 to 2005. Mr. Heerinckx also worked at Alza as part of the regulatory compliance team. He earned his Pharmacist Degree and Industrial Pharmacist Degree from the University of Leuven in Belgium.